abcam

ab189920

Anti-VPS11 antibody [EPR10344(2)]

Recombinant | RabMAb

Key facts

Isotype	IgG
Host species	Rabbit
Storage buffer	pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Form	Liquid
Clonality	Monoclonal
Immunogen	The exact immunogen used to generate this antibody is proprietary information.
Clone number	EPR10344(2)
Purification technique	Affinity purification Protein A
Concentration	0.496 mg/mL The concentration of this product may be batch-dependent Batch concentration finder →

Reactivity data

WB

Tested

Species	Mouse
Dilution info	1/1000 - 1/10000
Notes	-

Species	Human

Dilution info	1/1000 - 1/10000
Notes	-

Flow Cyt (Intra)

Tested

Species	Human
Dilution info	1/90
Notes	ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

Expected

Species	Mouse
Dilution info	Use at an assay dependent concentration.
Notes	-

IHC-P

Tested

Species	Human
Dilution info	1/250 - 1/500
Notes	-

Expected

Species	Mouse
Dilution info	Use at an assay dependent concentration.
Notes	-

Target data

See full target information VPS11

Function	Plays a role in vesicle-mediated protein trafficking to lysosomal compartments including the endocytic membrane transport and autophagic pathways. Believed

to act as a core component of the putative HOPS and CORVET endosomal tethering complexes which are proposed to be involved in the Rab5-to-Rab7 endosome conversion probably implicating MON1A/B, and via binding SNAREs and SNARE complexes to mediate tethering and docking events during SNARE-mediated membrane fusion. The HOPS complex is proposed to be recruited to Rab7 on the late endosomal membrane and to regulate late endocytic, phagocytic and autophagic traffic towards lysosomes. The CORVET complex is proposed to function as a Rab5 effector to mediate early endosome fusion probably in specific endosome subpopulations (PubMed:11382755, PubMed:23351085, PubMed:24554770, PubMed:25266290, PubMed:25783203). Required for fusion of endosomes and autophagosomes with lysosomes (PubMed:25783203). Involved in cargo transport from early to late endosomes and required for the transition from early to late endosomes (PubMed:21148287). Involved in the retrograde Shiga toxin transport (PubMed:23593995).

Storage

Shipped at conditions	Conditional Ambient
Appropriate short-term storage duration	1-2 weeks
Appropriate short-term storage conditions	+4°C
Appropriate long-term storage conditions	-20°C
Aliquoting information	Upon delivery aliquot
Storage information	Avoid freeze / thaw cycle

Notes

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Product promise

Tested

We have tested this species and application combination and it works. It is covered by our product promise.

Expected

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

Predicted

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

Not recommended

We do not recommend this combination. It is not covered by our product promise.


We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

---


4 product images



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VPS11 antibody [EPR10344(2)] (ab189920)

VPS11 Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) staining using rabbit Anti-VPS11 antibody


Immunohistochemical analysis of paraffin-embedded Human cervix carcinoma tissue labeling VPS11 with ab189920 at 1/500 dilution followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.



Flow Cytometry (Intracellular) - Anti-VPS11 antibody [EPR10344(2)] (ab189920)

VPS11 Flow Cytometry (Intracellular) staining using rabbit Anti-VPS11 antibody

Intracellular flow cytometric analysis of 2% paraformaldehyde-fixed Jurkat cells labeling VPS11 with ab189920 at 1/90 dilution (red), compared to a Rabbit monoclonal IgG isotype control (green), followed by Goat anti rabbit IgG (FITC) secondary antibody at 1/150 dilution.



Western blot - Anti-VPS11 antibody [EPR10344(2)] (ab189920)

All lanes:
Western blot - Anti-VPS11 antibody [EPR10344(2)] (ab189920) at 1/10000 dilution

Lane 1:
Human fetal brain tissue lysate at 20 µg

Lane 2:
K562 cell lysate at 20 µg

Lane 3:
293 cell lysate at 20 µg


Lane 4:
HeLa cell lysate at 20 µg

Secondary

All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 108 kDa

Observed band size: 108 kDa



Western blot - Anti-VPS11 antibody [EPR10344(2)] (ab189920)

VPS11 Western blot staining of RAW 264.7 cell lysate using rabbit Anti-VPS11 antibody

All lanes:
Western blot - Anti-VPS11 antibody [EPR10344(2)] (ab189920) at 1/1000 dilution

All lanes:
RAW 264.7 cell lysate at 10 µg

Secondary

All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution

Predicted band size: 108 kDa

Observed band size: 108 kDa

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.